Views: 1,687 | Downloads:
120
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Clinical Features, Management and Outcomes of high-grade glioma patients in Ramathibodi Hospital
Chansriwong P 
,
Sirisinha T
,
Sirisinha T Objective: To identify prognostic factors for survival and evaluate the effect of treatment on survival of patients
with high-grade glioma treated at Ramathibodi Hospital.
Material and Method: Medical records of patients with diagnosis of high-grade glioma registered in
Ramathibodi cancer registry were reviewed. A total of 36 patients were reviewed, only 27 patients were
included on survival analysis.
Results: Of the 36 patients, the male: female ratio was 1:1. Mean age of diagnosis was 41.86 years (range 18-
71 years). Histological findings were anaplastic glioma (22.20%), glioblastoma multiforme (63.90%) and
mixed glioma (13.90%). Of fifteen patients underwent total tumor removal, 17 patients had partial resection
and in 4 cases biopsy alone was done. Two third of the patients had received radiotherapy with mean total
dose 5,372 cGy. Nine patients also received chemotherapy (6 temozolomide and 3 BCNU). Median follow-up
time was 413.2 days. An overall survival time was 604.04 days and median disease free survival time was
402.45 days. In univariated analysis, the following favorable prognostic factors were identified: histological
findings of glioblastoma multiforme (GBM) and mixed glioma, received radiotherapy. In multivariate analysis,
radiotherapy improves overall survival significantly. Re-resection at recurrence did not appear to improve
overall survival.
Conclusion: Adult high-grade glioma had poor prognosis despite aggressive treatment. Radiotherapy significantly
improved survival while surgical tumor removal and chemotherapy did not. However due to the small
number of patients the further studies should be performed.
Keywords: Malignant Glioma, Temozolomide
with high-grade glioma treated at Ramathibodi Hospital.
Material and Method: Medical records of patients with diagnosis of high-grade glioma registered in
Ramathibodi cancer registry were reviewed. A total of 36 patients were reviewed, only 27 patients were
included on survival analysis.
Results: Of the 36 patients, the male: female ratio was 1:1. Mean age of diagnosis was 41.86 years (range 18-
71 years). Histological findings were anaplastic glioma (22.20%), glioblastoma multiforme (63.90%) and
mixed glioma (13.90%). Of fifteen patients underwent total tumor removal, 17 patients had partial resection
and in 4 cases biopsy alone was done. Two third of the patients had received radiotherapy with mean total
dose 5,372 cGy. Nine patients also received chemotherapy (6 temozolomide and 3 BCNU). Median follow-up
time was 413.2 days. An overall survival time was 604.04 days and median disease free survival time was
402.45 days. In univariated analysis, the following favorable prognostic factors were identified: histological
findings of glioblastoma multiforme (GBM) and mixed glioma, received radiotherapy. In multivariate analysis,
radiotherapy improves overall survival significantly. Re-resection at recurrence did not appear to improve
overall survival.
Conclusion: Adult high-grade glioma had poor prognosis despite aggressive treatment. Radiotherapy significantly
improved survival while surgical tumor removal and chemotherapy did not. However due to the small
number of patients the further studies should be performed.
Keywords: Malignant Glioma, Temozolomide
Download:
PDF